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a  b  s  t  r  a  c  t
We  report  optimized  workﬂows  for full-genome  sequencing  of  dengue  viruses  (DENVs)  1–4.  Based  on
alignments  of publicly  available  complete  genomes  we  modiﬁed  and  expanded  existing  primers  sets
to amplify  DENV  genotypes  that  were  previously  difﬁcult  or  impossible  to sequence.  We also  report
improvements  to  streamline  laboratory  handling,  including  a  dual  ampliﬁcation  strategy  for easy  and
difﬁcult  to sequence  “high-copy”  and  “low-copy”  templates,  respectively,  and normalization  of PCR
cycling  conditions  across  serotypes.  High-copy  templates  can  be  sequenced  following  ampliﬁcation  of
as few  as 5 overlapping  segments  covering  the  complete  viral  genome,  whereas  low-copy  templates  can
be  sequenced  following  ampliﬁcation  of  no more  than  10  overlapping  segments  of smaller  size.  These
changes  have  been  validated  using  a balanced  set  of wild-type  DENV  genomes  (11  of  DENV1,  14  of  DENV2,mplicon sequencing 13  of  DENV3  and  7  of DENV4)  derived  from  human  serum  samples  collected  throughout  South  Amer-
ica  over  the  past 15  years.  The  changes  described  enable  generation  of  complete  DENV  genomes  from
wild-type  samples  without  the  need  for  viral  enrichment  via  passaging  through  laboratory  cell lines.  This
should  facilitate  quick  and  cost-effective  generation  of  DENV  full-genome  sequences  of the  type  needed
for  accurate  epidemiological  surveillance  and  thorough  evolutionary  studies  of  wild-type  DENVs.
Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license  (http://. Introduction
Dengue fever remains a serious public health threat throughout
he world. According to the World Health Organization, dengue
iruses (DENVs) (family Flaviviridae; genus Flavivirus)  infect ∼390
illion people each year, result in 0.5 million hospitalizations,
nd lead to death in 2.5% of those affected (WHO, 2015). Using
odeling frameworks to map  the global distribution of dengue
isk others have estimated the dengue burden to be three times
igher than the estimate of the WHO  (Bhatt et al., 2013). Despite
he recent historic licensing of the ﬁrst dengue vaccine approved
or use in Mexico (Sanoﬁ-Pasteur, 2015), robust countermeasures
Abbreviations: DENVs, dengue viruses; NGS, next-generation sequencing; PGM,
ersonal genome machine.
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against DENVs continue to rely on a combination of vector con-
trol and surveillance efforts. All four DENV serotypes circulate in
South America, where almost all countries are hyper-endemic for
DENV transmission (Cafferata et al., 2016). Surveillance efforts in
these countries depend heavily on laboratory diagnostics that are
sensitive (such as PCR and ELISA based assays) and accurate (such
as direct sequencing) in order to track viral evolution and inform
public health interventions.
Several phylogenetic studies have documented the evolution of
DENVs in South America, highlighting the importance of continu-
ous monitoring of circulating DENV strains that could be linked to
severe forms of the disease and/or to clade displacement (Aquino
et al., 2008; Cruz et al., 2013; Dettogni and Louro, 2011; Forshey
et al., 2009; Kochel et al., 2008; Mendez et al., 2012; Oliveira et al.,
2010; Roca et al., 2009; Romano et al., 2010; Uzcategui et al., 2001;
Uzcategui et al., 2003). Many of these studies have focused on
envelope (E) gene sequences generated using traditional Sanger
sequencing (Sanger and Coulson, 1975; Sanger et al., 1977). Despite
being a major antigenic determinant, the E gene (∼1484 bp in
length) only provides limited phylogenetic information compared
to the complete viral genome (∼11 kb in length). The development
se (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Dual ampliﬁcation strategy for DENV1-4.
Gels show representative full-genome ampliﬁcations of all DENV serotypes, using both the 5- and 10-overlapping fragment approaches. Amplicons from the 5-fragment
approach from three serum samples of different Ct value (representing high-, medium- and low-copy templates) are shown in red, labeled in 1–5. Amplicons from the
10-fragment approach from low-copy templates only are shown in blue, labeled in A–J. M indicates the 1 kb plus DNA ladder.
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f robust next-generation sequencing (NGS) platforms has signif-
cantly lowered sequencing costs, enabling the use of complete
enome sequences to provide greater resolution of viral evolution-
ry dynamics. As a result, NGS technologies are now increasingly
sed for epidemiological surveillance and studies of viral genetic
iversity (Lequime et al., 2016; Rodriguez-Roche et al., 2016; Sim
t al., 2015). Unfortunately, the protocols developed for NGS of
ENVs have mainly focused on viral strains that have circulated
n Asia (Parameswaran et al., 2012; Sim et al., 2015; Zhao et al.,
014). Given that strains of DENVs circulating in South America can
how signiﬁcant genetic variation (Rodriguez-Roche et al., 2016;
omano et al., 2013), and especially when compared to those from
sia, existing protocols for full-genome ampliﬁcation of DENVs can
ail to generate complete genomes from American samples.
Here we describe changes made to existing sets of primers
Christenbury et al., 2010; Rodriguez-Roche et al., 2016) in order
o optimize workﬂows and reliably generate full genomes of South
merican DENV strains. Speciﬁcally, we have implemented three
ets of changes: the ﬁrst ifs a complete re-design and expansion
f primers used for amplicon sequencing of DENV1-4; the sec-
nd is the development of a dual approach strategy for both high-
nd low-copy viral templates; the last is the inclusion of an ini-
ial viral quantiﬁcation step that informs whether the high- or
ow-copy ampliﬁcation approach should be used. Together, these
hanges streamline laboratory handling, reduce costs, and enable
eneration of complete genome data from DENV samples that were
reviously difﬁcult, or even impossible to sequence.
. Materials and methods
.1. Amplicon generation
Nucleic acids were extracted using QIAamp Viral RNA Mini Kit
Qiagen 52906) according to the manufacturer’s instructions and
onverted to cDNA using serotype-speciﬁc primers targeting the
′-ends of viral genomes (Table 1). Brieﬂy, 20-L reactions con-
aining 10 L nucleic acids, 1 L 10 M gene-speciﬁc primer, 1 L
uperScriptTM III (Invitrogen 18080-044), 4 L 5X RT buffer, 1 L
.1 M DTT, 1 L 10 mM of each dNTPs, 1 L RNaseOUTTM (Invit-
ogen 10777-019), and 1 L nuclease-free water were incubated at
0 ◦C for 60 min  and then terminated at 75 ◦C for 15 min. Amplicons
ere generated in 50-L reactions containing 2 L DENV cDNA,
 L each 10 M forward and reverse primers, 0.5 L PlatinumTM
aq DNA Polymerase High Fidelity (Invitrogen 11304-029), 5 L
0X HiFi PCR Buffer, 1.5 L 50 mM MgSO4, 1 L 10 mM dNTPs,
0 L 5X Q solution (supplied withTaq DNA Polymerase, Qiagen
01203), and 28 L nuclease-free water. The cycling conditions
onsisted of 40 cycles of denaturation (94 ◦C for 30 s), annealing
47 ◦C (DENV1), 53 ◦C (DENV2), 42 ◦C (DENV3) and 52 ◦C (DENV4)
or 30 s), and extension (72 ◦C for 3 min), with a ﬁnal extension
t 72 ◦C for 5 min. Amplicons were visualized by agarose gel elec-
rophoresis and puriﬁed either directly or by gel extraction using
IAquick Gel Extraction Kits (Qiagen 28706).
.2. Sequencing
Prior to library preparation, overlapping amplicons were quan-
iﬁed by NanoDrop 1000 (Thermo-Fisher) and pooled in equimolar
mounts in order to cover the length of each genome. Pools
ere used to prepare sequencing libraries optimized for both
GM and MiSeq sequencing platforms, according to the man-
facturer’s instructions. Brieﬂy, PGM libraries were constructed
sing Bioruptor (Diagenode) fragmented samples, Ion Xpress Bar-
ode Adapters (Thermo-Fisher 4474517) and Ion Plus Fragment
ibrary Kits (Thermo-Fisher 4471252). MiSeq libraries were con- Methods 235 (2016) 158–167
structed using enzymatically-fragmented samples, Nextera DNA
Indexes (Illumina FC-121-1011) and Nextera DNA Library Prepa-
ration Kits (Illumina FC-121-1030). QC was  done by Bioanalyzer®
(Agilent) using High Sensitivity DNA chips (Agilent 5067-4627)
and by Qubit® (Thermo-Fisher) using Qubit®dsDNA HS Assay Kits
(Thermo-Fisher Q32854). Prior to sequencing, barcoded libraries
were pooled as recommended for each sequencing platform.
Brieﬂy, PGM libraries were diluted to 12 pM,  ampliﬁed by emul-
sion PCR on the Ion OneTouchTM 2 Instrument (Thermo-Fisher)
using Ion PGMTM Template OT2 200 Kits v2 (Thermo-Fisher
4480974), and enriched on the Ion OneTouchTM ES enrichment
System (Thermo-Fisher), according to the manufacturer’s instruc-
tions. PGM libraries were sequenced on the Ion PGM  platform
(Thermo-Fisher) using Ion PGMTM sequencing 200 kits v2 (Thermo-
Fisher 4482006) and Ion 314TM Chips (Thermo-Fisher 4482261).
MiSeq libraries were diluted to 12 pM and sequenced on the MiSeq
platform (Illumina) using MiSeq v3 600 cycle kits (Illumina MS-
102-3003). Bioinformatics processing was carried out using the
EDGE platform (Lo, personal communication;) and custom scripts.
3. Results
3.1. Primer design
Sequences of all primers used for targeted ampliﬁcation of
DENV1-4 are listed in Table 1. The primers for each serotype were
designed to share annealing temperatures so that they could be
used interchangeably within each set. The primer sets for DENV1,
2 and 3 consist of 20 primers each with an annealing tempera-
ture of 47 ◦C, 53 ◦C and 42 ◦C, respectively; the DENV4 set consists
of 18 primers with an annealing temperature of 52 ◦C. To ensure
that each set would amplify South American DENV strains we ﬁrst
downloaded representative full genome sequences for DENVs that
have circulated in the region since 2000 (Table 2). Speciﬁcally,
81 representative complete genomes (23 of DENV1, 18 of DENV2,
29 of DENV3 and 11 of DENV4) from Argentina, Brazil, Colombia,
Paraguay, Peru and Venezuela available from public databases were
used as references. These were carefully selected to maximize
diversity in terms of serotype, year of isolation, and geographical
origin. Previously published sets of DENV primers (Christenbury
et al., 2010; Rodriguez-Roche et al., 2016) were also used to guide
our design. In some cases, primers included degenerate or semi-
degenerate bases. Primers were positioned to generate overlapping
amplicons spanning the complete length of each DENV genome in
as few steps as possible (Fig. 1). Given that ampliﬁcation success is
linked to target amplicon size and to template concentration, we
anticipated that long amplicons from low-copy templates would be
harder to generate than short amplicons from high-copy templates.
Thus, our design considers both high- and low-copy ampliﬁcation
strategies in order to ensure full-genome ampliﬁcation in a range
of starting template concentrations. High-copy templates are fully
covered by as few as 5 overlapping amplicons, whereas low-copy
templates are fully covered by no more than 10 amplicons. Overall,
target amplicon size ranges between ∼1 and ∼3 kb.
3.2. Targeted full-genome ampliﬁcation and sequencing
To test the modiﬁcations introduced in our primers, we selected
a set of 43 DENV positive samples (9 of DENV1, 14 of DENV2, 13 of
DENV3 and 7 of DENV4) consisting of acute-phase sera (Table 3)
collected during routine febrile surveillance programs conducted
between 2000 and 2015 by investigators from the U.S. Naval
Medical Research Unit No.6 in Peru and neighboring coun-
tries (Bolivia, Ecuador, Paraguay, Venezuela), with institutional
review board approval from all implicated partners (proto-
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Table  1
Primer sequences used for full-genome ampliﬁcation of DENV1-4.
All primers, with the exception of d3a10 (*), are either new or modiﬁed for this work. Primers for each serotype share annealing temperatures, which enables interchangeable
use  within each set. Genome locations are reported with respect to GenBank isolates JX669464 for DENV1, KC294222 for DENV2, JX669501 for DENV3, and JN983813
for  DENV4. The last primer of the 3′ end in each set (shown in red) was used for reverse transcription (note that all reverse transcription reactions were carried out at
50 ◦C regardless of primer annealing temperature). In the 5-fragment ampliﬁcation strategy individual overlapping amplicons are named 1–5, whereas in the 10-fragment
ampliﬁcation strategy individual overlapping amplicons are named A-J (except for DENV4, where the last overlapping amplicon (named 5 and/or I) is shared by both the 5-
and  10-fragment ampliﬁcation strategies.
Serotype Primer Name Sequence 5′-3′ Location 10 Products 5 Products Annealing Temperature
DENV-1 DEN1 CC AF ACGTGGACCGACAAGAACAGTTTCG 13–37 A ∼1.65Kb 1 ∼2.55Kb 47 ◦C
DEN1  CC 1R CTTCCTGTTTCTTTGCATGAGCTGTC 1657–1682
DEN1 CC 1F GAGCATGGAAGCTGCGTCACCAC 1010–1032 B ∼1.55Kb
DEN1 CC BR CTTYCCAATGGCTGCTGACAGTCTT 2539–2563
DENV1-LAB-5F-CC CGCATGGGACTTCGGYTCTATAGG 2191–2213 C ∼1.40Kb 2 ∼2.50Kb
DEN1 CC 2R TGTTCCAGTCATCAGCATCTTTCTAC 3558–3583
DEN1 CC 2F ATTGCGTGACTCCYACACCCAAATG 2930–2953 D ∼1.75Kb
DEN1 CC DR CCTGGTGACGTGCCACATTGTGTG 4658–4681
DENV1-LAB-8F-CC CAAAGAGGACTGTTGGGCAGGTCC 4600–4620 E ∼1.65Kb 3 ∼2.35Kb
DEN1 CC 3R ATCTCCACGTCCATGTTCTCCTCC 6241–6264
DEN1 CC 3F TCATGGAACTCAGGCTACGACTGG 5549–5572 F ∼1.40Kb
DENV1-LAB-10R-CC CTGCATAGAGRGTCCAGGCTGAAG 6933–6956
DENV1-LAB-12F-CC CACAAAGAAAGACCTGGGGATTGGC 6850–6874 G ∼1.50Kb 4 ∼2.25Kb
DEN1 CC 4R GTTCCACTGCCACATGTCTTGTTCC 8351–8375
DEN1 CC 4F GAGAAACAACCAAACATGCAGTGTCG 7716–7741 H ∼1.40Kb
DENV1-LAB-14R-CC TTGTGCAGTCCTTCTCCTTCCACTC 9087–9111
DENV1-LAB-14F-CC TACGTGTTCTAAARATGGTGGAACCAT 8058–8084 I 5 ∼2.65Kb
DEN1 CC 5R AGCCATAAGTTCCGACCTGTCCAC 9372–9395 ∼1.35Kb
DEN1 CC 5F ACTGACATCATGGAGCCTGAACATG 9230–9254 J
DEN1 CC JR CGTTCTGTGCCTGGAATGATGCTG 10684–10707 ∼1.45Kb
DENV-2 d2s1C CC AGTTGTTAGTCTACGTGGACCGACA 1–25 A ∼1.50Kb 1 ∼2.45Kb 53 ◦C
DEN2  CC 1R AGCACCATCTCATTGAAGTCGAGG 1506–1529
DEN2 CC 1F CAAACACTCCATGGTAGACAGAGG 1212–1235 B ∼1.25Kb
d2a18-CC TCCCRCTGCCACATTTCARTTCTTT 2455–2474
d2s4-CC ACGCSAAGAAACAGGATGTYGTTGT 1669–1690 C ∼1.55Kb 2 ∼2.75Kb
DEN2 CC 2R TCCTGCTGTTTGTGTATGGTAGCC 3196–3219
DEN2 CC 2F CACATGGAAGATGGAGAAAGCCTC 3045–3068 D ∼1.35Kb
d2a14-CC GCCGTRATTGGTATYGATACWGGAA 4401–4425
d2s8-CC ATGGGMGTGACTTAYCTTGCCCTA 3686–3704 E ∼1.45Kb 3 ∼2.80Kb
DEN2 CC 3R CTTCTCTAACTATGGCTGGAAGG 5130–5152
DEN2 CC 3F TGGTGTTGTCACAAGGAGTGGAG 4976–4998 F ∼1.50Kb
d2a10-CC TACGCCYTTCCRCCTGCYTCAG 6477–6497
d2s13-CC GCAGACAGAARGTGGTGTTTTGATG 6193–6213 G ∼1.15Kb 4 ∼2.30Kb
DEN2 CC 4R CATTAATACTTGAGTCACGCAGAGG 7350–7374
DEN2 CC 4F TTCAAGCAAAAGCAACCAGAGAAGC 7199–7223 H ∼1.25Kb
d2a6-CC CATGGTAWGCCCAYGTTTTGTATGG 8468–8488
d2s16-CC CAGGAAGTGGATAGAACCYTRGCA 7669–7692 I ∼1.65Kb 5 ∼3.05Kb
DEN2 CC 5R CATTACTGTGCCTCTTGGTGTTGG 9316–9339
DEN2 CC 5F CTGGTTGACAGGGAAAGAAATCTCC 8870–8893 J ∼1.85Kb
d2a5B-CC AGAACCTGTTGATTCAACAGCACCAT 10706–10725
DENV-3 d3s1C CC AGTTGTTAGTCTACGTGGACCG 1–22 A ∼1.55Kb 1 ∼2.30Kb 42 ◦C
DEN3  CC 1R CATGCTTTGTTCTTCATTGTTAGC 1524–1547
DEN3 CC 1F CAACATAACAACTGACTCAAGATG 1132–1155 B ∼1.20Kb
DEN3 CC BR CAAGTCAAGAGAACTCCTATTCC 2300–2322
d3s5-CC CTGAACCTCCTTTTGGGGAAAG 2035–2053 C ∼1.55Kb 2 ∼2.30Kb
DEN3 CC 2R CTCCATGTTATTTGCCCTGAGA 3599–3621
DEN3 CC 2F AGGTGGAAGATTACGGGTTCG 2874–2894 D ∼1.45Kb
d3a14-CC AACTGTGATCATTAARTTGTGGGA 4334–4356
DEN3 CC EF TTCTCTCCTTAGAAATGATGTACC 4180–4203 E ∼1.05Kb 3 ∼2.15Kb
DEN3 CC 3R TCAATGCTTCTTCCATCTCAGC 5201–5222
DEN3 CC 3F GAGTGGTTACAAAGAATGGTGG 4971–4992 F ∼1.35Kb
d3a10* GCYGCAAARTCCTTGAATTCCT 6339–6360
d3s13-CC CCAGCTCTCTTTGARCCAGAAA 6032–6053 G ∼1.30Kb 4 ∼2.30Kb
DEN3 CC 4R AGCATAACCTGTCCCAGTTGC 7318–7338
DEN3 CC 4F AGATGTGGACTTGCACCCAGC 6904–6924 H ∼1.45Kb
d3a6-CC2 CGCATTAACATGTCGAGTTCC 8342–8361
DEN3 CC IF TCCACTTTCACGAAACTCCACG 8185–8206 I ∼1.25Kb 5 ∼2.50Kb
DEN3 CC 5R TTCAGACCATAAGTTCCTACCTG 9368–9390
DEN3 CC 5F GAAGATGACCTGCACAATGAGG 9191–9212 J ∼1.50Kb
DEN1 CC JR CGTTCTGTGCCTGGAATGATGCTG 10646–10669
DENV-4 d4s1C CC AGTTGTTAGTCTGTGTGGACCGACAA 1–26 A ∼1.45Kb 1 ∼2.15Kb 52 ◦C
DEN4  CC 1R GTGACCTGGGAGTTATCGTGGCTG 1420–1443
DEN4 CC 1F GACACCCATGCAGTAGGAAATGACAC 1377–1402 B ∼0.80Kb
DEN4 CC BR ACTCAAACATCTTGCCAATGGAACTC 2123–2148
d4s5-CC CTCCGTGTAAAGTCCCCATAGAGATAA 1910–1933 C ∼1.75Kb 2 ∼3.05Kb
DEN4 CC 2R CATGATGAGGGCTCGTAGCAAGTCC 3632–3656
DEN4 CC 2F AGAAGATGGGTGCTGGTATGGGATG 3398–3422 D ∼1.55Kb
DEN4 CC DR ACTCCATTTCCATAGAGTCCGATGAC 4959–4984
DEN4 CC EF GACTGGGAGATTGGAGCCATCTTG 4706–4729 E ∼1.50Kb 3 ∼2.60Kb
162 C.D. Cruz et al. / Journal of Virological Methods 235 (2016) 158–167
Table 1 (Continued)
Serotype Primer Name Sequence 5′-3′ Location 10 Products 5 Products Annealing Temperature
DEN4 CC 3R TCTTTGTAAGAAATGCCAGCAGAAGC 6175–6200
DEN4 CC 3F CTCAAGCCAGTTATCCTAACAGATGG 5809–5834 F ∼1.50Kb
d4a8-CC CATGACYTGCCCTAATTGCTTTTCAAA 7289–7311
d4s16-CC GAAAAGRACAGCTGCTGGRATCATGA 7205–7226 G ∼1.40Kb 4 ∼2.45Kb
DEN4 CC 4R TCTGTCATGGCTAACTGAGTCACCA 8573–8597
DEN4 CC 4F TTCACAACAAGGCATAGGAAACCCAC 8290–8315 H ∼1.40Kb
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od4a3-CC TGTGRAARTGGTGGGAGCAAAAAGGA 
d4s21-CC GAAAGAYATYCCGCAGTGGGAACCA 
d4a5B-CC AGAACCTGTTGGATCAACAACACCAAT 
ols NMRCD.2000.0006, NMRCD.2000.0008, NMRCD.2001.0002,
MRCD.2005.0008, NMRCD.2010.0010, NAMRU6.2014.0028,
AMRU6.2015.0010). In two additional instances for DENV1, we
lso used infected culture supernatants derived from samples. To
ddress the issue of template concentration, DENV genomes were
nitially quantiﬁed using a previously described qRT-PCR protocol
hat targets a conserved region in all DENV serotypes (McAvin
t al., 2005), and thus, can be used to compare DENV-speciﬁc
NA concentrations across serotypes. McAvin cycle threshold
Ct) values for the samples tested ranged between 18 and 37.
s expected, samples with high concentration of DENV template
Ct values lower than 26) were easily ampliﬁed (Fig. 1). In these
ases, complete genome coverage was achieved with as few as 5
verlapping amplicons. As the concentration of DENV template
ecreased (Ct values between 26 and 29), ampliﬁcation efﬁciency
or large amplicons also decreased. In these cases of medium and
ow concentration of DENV template, complete genome coverage
as achieved by increasing the number of overlapping amplicons
p to 10 (Fig. 1). In the case of extremely low concentrations
f DENV template (Ct values of 29 and higher), at least some
verlapping fragments could be generated using the 10-fragment
mpliﬁcation strategy (not shown). However, we consider that
bove Ct values of 29, DENV samples are sub-optimal for the
urposes of amplicon sequencing by NGS. Although it is possible
hat further optimization of the PCR conditions could improve the
enome coverage in samples of extremely low concentration of
ENV template, such efforts were beyond the scope of this work.
Once generated by PCR, amplicons representing the total length
f each tested DENV genome were pooled together and sequenced
sing both Illumina MiSeq and Ion Torrent PGM sequencing
latforms at different depths of coverage (Fig. 2). Our targeted
mpliﬁcation strategy results in full-genome coverage of all DENV
erotypes for every overlapping fragment in each sample. Sequenc-
ng statistics for representative samples are shown in Table 4.
etween 93% and 99+% of all reads in each sample corresponded
o DENV sequences, indicating this is an effective ampliﬁcation
nd sequencing strategy for DENVs that have circulated in South
merica since the year 2000.
. Discussion
Amplicon sequencing by NGS is a relatively simple technique, at
east in theory. In practice however, the generation of overlapping
mplicons that cover the complete length of a particular genome
f interest can be complicated by a number of factors, includ-
ng template concentration, sequence diversity, primer speciﬁcity,
nd PCR ampliﬁcation efﬁciency. In the current study we report
mprovements to existing full-genome ampliﬁcation strategies for
ENVs (Christenbury et al., 2010). These changes should beneﬁt
hose attempting to generate complete DENV genomes in a quick
nd cost-effective manner, particularly for DENV strains that have
irculated in South America since 2000.
The ﬁrst modiﬁcation we have implemented is the inclusion
f an initial serotype-independent relative quantiﬁcation of DENV–9689
–9631 I ∼1.00Kb 5 ∼1.00Kb
0–10650
genome copies using qPCR (McAvin et al., 2005). The advantages
of using viral load, as measured by qPCR, to guarantee successful
ampliﬁcation of DENVs from acute serum samples has been pre-
viously documented (Rodriguez-Roche et al., 2012). Because this
assay targets a conserved region in all DENV genomes it can be
used to compare DENV-speciﬁc genome copies across serotypes.
Our results clearly indicate that DENV positive samples showing
Ct values of up to 29 are suitable starting material for this ampli-
con sequencing strategy. In contrast, DENV positive samples with
Ct values higher than 29 are not suitable, even for the 10-fragment
ampliﬁcation strategy developed for “low-copy” templates. Despite
being DENV positive, such samples contain sub-threshold levels
of DENV RNA that render them sub-optimal because they only
lead to partial genome ampliﬁcation. By establishing the relative
concentration of starting material at the outset of the amplicon
sequencing strategy, the researcher is able to focus on samples
that have a high probability of success and avoid potentially costly
and time-consuming preparation of samples that are a dead-end.
A possible workaround for “low-copy” templates is to passage
viruses through an established tissue culture line, like C6/36 cells
(Singh and Paul, 1969; Tesh, 1979). However, the drawback to this
approach is that viruses may  mutate and adapt to the host cell
type (Villordo et al., 2015). Thus, it is always preferable to generate
amplicon-sequencing data from samples that have not been sub-
jected to laboratory culture (Rodriguez-Roche et al., 2012). This is
particularly important in downstream applications that assess viral
evolution, since by avoiding passage through a laboratory culture
one also avoids the introduction of mutations that are not repre-
sentative of viruses circulating in the wild. In this study, we  have
tested a total of 46 samples, representing all four DENV serotypes.
All samples reported here were human serum samples, which is
signiﬁcant for two  reasons. First, serum samples contain viruses
that have not been subject to passage through laboratory cell lines,
and thus, they represent wild-type viruses that have actually cir-
culated in nature. Second, serum samples tend to have much lower
viral RNA concentrations that those found of cultured samples, thus
a methodology that can successfully generate full genomes from
wild-type viruses in serum samples is robust. In some instances
we have also sequenced cultured samples, indicating the primer
sets described can be used both for “easy-to-sequence” cultured
samples and for “high-value” wild-type samples.
The second modiﬁcation we have implemented is a dual
approach for high- and low-copy templates. High-copy templates
(with Ct values as high as 26) can be easily covered in full by as few
as 5 overlapping amplicons, whereas low-copy templates (with Ct
values between 26 and 29) can be covered by no more than 10.
Given that the relative concentration of starting template in the
sample is determined before amplicon sequencing takes place, the
researcher again has an added level of control that informs strat-
egy and enables selection of the most appropriate ampliﬁcation
strategy. Perhaps this ﬂexibility is not very signiﬁcant in the con-
text of a handful of genomes, but when hundreds or thousands of
full genomes need to be generated accurately, quickly, and consis-
tently, tailored strategies that increase the possibilities of success
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Table  2
DENV complete genome sequences used as references for primer design.
Sequences were carefully selected to maximize diversity in terms of serotype, year of isolation, and country of origin.
Serotype Accession # Year Location Length (bp)
DENV-1 FJ850070 2000 Brazil 10677
GU131832 2000 Venezuela 10460
FJ850073 2001 Brazil 10692
GU131948 2001 Colombia 10627
GU131834 2001 Venezuela 10468
FJ850075 2002 Brazil 10683
FJ850077 2003 Brazil 10684
FJ850081 2004 Brazil 10688
FJ639796 2004 Venezuela 10676
FJ850084 2005 Brazil 10686
KJ189304 2005 Colombia 10447
FJ639812 2005 Venezuela 10640
FJ850087 2006 Brazil 10690
GQ868563 2006 Colombia 10661
HQ332182 2006 Venezuela 10735
FJ850090 2007 Brazil 10673
GQ868567 2007 Colombia 10690
HQ332183 2007 Venezuela 10735
FJ850093 2008 Brazil 10690
GQ868570 2008 Colombia 10674
FJ850104 2008 Venezuela 10690
KC692513 2010 Argentina 10735
JX669462 2010 Brazil 10759
DENV-2 FJ898466 2000 Venezuela 10679
FJ850074 2001 Brazil 10678
FJ850076 2002 Brazil 10663
KC294222 2002 Peru 10723
FJ850078 2003 Brazil 10667
FJ850082 2004 Brazil 10679
FJ639788 2004 Venezuela 10678
FJ850085 2005 Brazil 10677
FJ850088 2006 Brazil 10667
FJ850091 2007 Brazil 10678
GQ868558 2007 Colombia 10679
KC294200 2007 Peru 10724
EU482607 2007 Venezuela 10679
GQ199890 2008 Brazil 10679
FJ850107 2008 Venezuela 10667
KC294201 2009 Peru 10723
KC294223 2010 Peru 10723
KC294218 2011 Peru 10723
DENV-3 FJ898457 2000 Ecuador 10663
FJ898468 2000 Venezuela 10663
FJ913015 2001 Brazil 10663
GU131950 2001 Colombia 10616
GQ252678 2001 Venezuela 10641
GQ868571 2002 Colombia 10663
FJ898458 2002 Peru 10663
FJ898471 2002 Venezuela 10663
FJ898447 2003 Brazil 10663
GU131952 2003 Colombia 10638
FJ898473 2003 Venezuela 10663
FJ850083 2004 Brazil 10663
GU131953 2004 Colombia 10588
KJ189266 2004 Peru 10696
JX669501 2005 Brazil 10707
KJ189299 2005 Peru 10692
GU131865 2006 Brazil 10501
GU131954 2006 Colombia 10525
KJ189297 2006 Peru 10692
FJ639825 2006 Venezuela 10648
FJ850092 2007 Brazil 10648
GQ868578 2007 Colombia 10659
HQ235027 2007 Paraguay 10707
KJ643590 2007 Peru 10692
FJ850111 2007 Venezuela 10663
FJ850094 2008 Brazil 10662
KJ189301 2008 Peru 10693
FJ639827 2008 Venezuela 10635
JF808120 2009 Brazil 10707
DENV-4 FJ639748 2000 Venezuela 10551
GQ868582 2001 Colombia 10606
FJ639773 2001 Venezuela 10606
GQ868584 2004 Colombia 10552
GQ868585 2005 Colombia 10606
164 C.D. Cruz et al. / Journal of Virological Methods 235 (2016) 158–167
Table 2 (Continued)
Serotype Accession # Year Location Length (bp)
JN819406 2006 Venezuela 10357
GQ868643 2007 Venezuela 10593
FJ882592 2008 Venezuela 10606
JN983813 2010 Brazil 10649
JQ513335 2011 Brazil 10604
KJ596671 2012 Brazil 10649
Table 3
Samples used for protocol validation.
Most samples are human serum containing wild-type DENVs. In two  instances for DENV1, supernatants from cultured serum samples were also used.
Serotype Sample Code Year Location Sample Type Ct value
DENV-1 OBS9842 2000 Peru culture 22.03
FSB2837 2009 Bolivia culture 12.63
FCB0983 2009 Bolivia serum 37.27
FSE7098 2010 Ecuador serum 32.39
FPA2544 2010 Paraguay serum 31.59
FSP1646 2010 Peru serum 26.44
FYA00055 2011 Paraguay serum 28.61
FEG00002 2012 Ecuador serum 35.07
FPJ00740 2014 Peru serum 24.68
FYC00721 2015 Paraguay serum 22.93
FPJ00811 2015 Peru serum 21.45
DENV-2 FVB2118 2011 Bolivia serum 20.95
FVB2121 2011 Bolivia serum 26.11
FPI00403 2011 Peru serum 22.1
FEG00005 2012 Ecuador serum 32.34
FPI04256 2012 Peru serum 23.30
FYA00328 2013 Paraguay serum 23.61
FPI06921 2013 Peru serum 22.60
FPY00498 2014 Peru serum 20.69
FPU00873 2014 Peru serum 32.32
FPI10982 2014 Peru serum 25.54
FPM00818 2014 Peru serum 28.64
FPI13322 2015 Peru serum 22.41
FPP02381 2015 Peru serum 23.43
FVM00186 2015 Venezuela serum 26.17
DENV-3 IQD3765 2002 Peru serum 20.99
FSB0417 2003 Bolivia serum 25.28
FSL1212 2003 Peru serum 19.35
FSE1036 2004 Ecuador serum 22.36
FSB0879 2005 Bolivia serum 28.56
FSB0931 2005 Bolivia serum 22.87
IQE2562 2005 Peru serum 18.64
IQE3021 2006 Peru serum 18.53
FCB0589 2007 Bolivia serum 23.82
FPA0171 2007 Paraguay serum 28.58
FPA0313 2007 Paraguay serum 23.16
FPI13521 2015 Peru serum 20.89
FPP02377 2015 Peru serum 18.36
DENV-4 FSL3797 2008 Peru serum 26.73
FSL3887 2009 Peru serum 26.37
FSP1830 2010 Peru serum 27.81
FMD3542 2010 Peru serum 27.32
FPM00691 2013 Peru serum 28.24
FPM00697 2013 Peru serum 28.03
FVM00212 2015 Venezuela serum 21.55
Table 4
Sequencing statistics for sequenced DENV samples.
Following PCR ampliﬁcation, overlapping fragments were pooled in roughly equimolar amounts in order to cover the length of each genome. Pools were prepared into both
Ion  and Illumina libraries and sequenced using PGM and MiSeq platforms, respectively, at different depths of coverage.
Ion Torrent Data MiSeq Data
Sample Serotype Total Reads Total Bases DENV Reads % DENV Reads Total Reads Total Bases DENV Reads %DENV Reads
1 DENV-1 581 90,570 548 94.32% 582,328 174,440,938 581,361 99.83%
2  DENV-1 4,136 702,875 3,960 95.74% 841,056 252,934,514 815,656 96.98%
3  DENV-2 500 54,731 466 93.20% 444,294 293,192,662 424,307 95.50%
4  DENV-2 6,179 908,554 5,944 96.20% 1,353,824 405,714,890 1,343,717 99.25%
5  DENV-2 82,997 11,132,821 79,689 96.01% 946,264 283,873,702 938,124 99.14%
6  DENV-3 3,603 560,731 3,545 98.39% 926,635 277,773,636 909,683 98.17%
7  DENV-4 3,592 568,281 3,555 98.97% 901,131 269,778,474 898,848 99.75%
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Fig. 2. Representative depth of coverage plots for DENV1-4.
DENV1 and 3 were sequenced on the Ion Torrent platform at a low depth of coverage (50X on average), whereas DENV2 and 4 were sequenced on the MiSeq platform at a
high  depth of coverage (1,500X on average). DENV1, 2 and 4 coverage plots were derived from 5 “long” overlapping fragments (shown in red with labels 1–5), whereas the
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hile reducing costs, time and handling, can have a very signiﬁcant
ositive impact.
The ﬁnal modiﬁcation we have implemented is a complete re-
esign of primer sequences with the dual purpose of ensuring
uccessful ampliﬁcation of DENV strains that have circulated in
outh America, and of normalizing annealing temperatures for all
rimers within each serotype set. South American DENV strains are
ften poorly ampliﬁed, if ampliﬁed at all, by existing primer sets
Christenbury et al., 2010; Rodriguez-Roche et al., 2016) because
hose primers have been developed for DENV strains that have
rimarily circulated in Asia. In addition, some of these primer
ets have been developed using clinical isolates where speciﬁc
erotypes predominated over others (introducing bias towards the
ver-represented serotype(s)), or using viruses that have been
assaged through laboratory cell lines (introducing bias towards
aboratory-adjusted strains). The primer sets described here have
een validated using balanced samples sets composed of diverse
ild-type DENV genomes derived from human serum samples rep-
esenting all four DENV serotypes and a variety of geographical
egions in South America over a 15-year period. These primer sets
ave the added beneﬁt of sharing annealing temperatures, which
hould streamline handling by enabling interchangeable use at a
ingle annealing temperature within each set. Once again, the aim
as been to simplify workﬂows as much as possible in order to
ncrease processing output while maintaining or improving PCR
mpliﬁcation efﬁciency for South American strains that were pre-
iously difﬁcult or impossible to sequence. This added efﬁciency
hould be particularly relevant during outbreaks, when a labora-
ory may  be required to process increased numbers of samples in
 short period of time. the case of DENV4, the last overlapping fragment is the same in both the high and
DENVs are known for their genetic variation within serotype
groups and geographical regions (Rico-Hesse, 2003; Rodriguez-
Roche et al., 2012; Weaver and Vasilakis, 2009). Our targeted
amplicon-sequencing strategy aims to normalize and facilitate
workﬂows that can be cumbersome, expensive, and time-
consuming, particularly if they are attempted on samples with
sub-optimal concentrations of viral genomes that fail to yield
complete genome sequences. We  have shown that the modiﬁca-
tions implemented result in successful generation of overlapping
amplicons that can be processed using different library con-
structions approaches and NGS platforms. Speciﬁcally, we have
processed a diverse group of wild-type DENV sequences derived
from serum using both mechanical and enzymatic library construc-
tion approaches, two separate sequencing platforms (Ion Torrent
and MiSeq), and two different depths of coverage (DENV1 and
DENV3 at a low depth of 50X on average, and DENV2 and DENV4 at a
high depth of 1,500X on average). Nevertheless, we have avoided a
detailed discussion of sequencing statistics, including depth of cov-
erage and error rates for example, in order to highlight the ﬂexibility
of this approach, which allows the researcher to control different
aspects of sequencing in order to suit a variety of applications that
may  require dramatically different levels of depth of coverage. The
main advantage of this sequencing strategy is that the majority of
sequencing reads obtained (97% on average) correspond to DENVs.
This has the added beneﬁt of simplifying downstream bioinformat-
ics processing because a reduced number of “contaminating” reads
is an advantage over non-targeted methods like shotgun sequenc-
ing, where a large number of host-speciﬁc reads often impede
adequate representation of the complete viral genome of interest
(Yozwiak et al., 2012). We  believe this methodology has a number of
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ownstream applications, including epidemiological surveillance,
tudies of quasi-species and dominant genomes, and studies of
ENV evolution where measurements of intra-host diversity can
e used to identify evolutionary forces (e.g.: natural selection vs.
enetic drift) that act on viral populations, particularly in the case
f DENV strains like the ones that have circulated in South America
ver the last 15 years.
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